These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21867933)

  • 1. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.
    Holmes JA; Desmond PV; Thompson AJ
    Clin Liver Dis; 2011 Aug; 15(3):497-513. PubMed ID: 21867933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
    J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
    Lange CM; Zeuzem S
    J Hepatol; 2011 Sep; 55(3):692-701. PubMed ID: 21440591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.
    Venegas M; Brahm J; Villanueva RA
    Ann Hepatol; 2012; 11(6):827-37. PubMed ID: 23109445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
    Ochi H; Maekawa T; Abe H; Hayashida Y; Nakano R; Kubo M; Tsunoda T; Hayes CN; Kumada H; Nakamura Y; Chayama K
    Gastroenterology; 2010 Oct; 139(4):1190-7. PubMed ID: 20637204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.
    Rembeck K; Lagging M
    Pharmacogenomics; 2015; 16(10):1179-88. PubMed ID: 26250055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
    Rembeck K; Waldenström J; Hellstrand K; Nilsson S; Nyström K; Martner A; Lindh M; Norkrans G; Westin J; Pedersen C; Färkkilä M; Langeland N; Buhl MR; Mørch K; Christensen PB; Lagging M
    Hepatology; 2014 Jun; 59(6):2131-9. PubMed ID: 24519039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.
    Cariani E; Villa E; Rota C; Critelli R; Trenti T
    Clin Chem Lab Med; 2011 Aug; 49(8):1247-1256. PubMed ID: 21612542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?
    Orlent H; Reynaert H; Bourgeois S; Dideberg V; Adler M; Colle I; De Maeght S; Laleman W; Michielsen P; Moreno C; Mulkay JP; Stärkel P; Delwaide J;
    Acta Gastroenterol Belg; 2011 Jun; 74(2):317-22. PubMed ID: 21861317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The function and application of the IL28B gene in HCV infection and treatment].
    Ma K; Zhang AM; Xia XS
    Yi Chuan; 2013 Nov; 35(11):1244-52. PubMed ID: 24579307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
    Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
    Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
    Rivero-Juarez A; Lopez-Cortes LF; Camacho A; Caruz A; Torres-Cornejo A; Martinez-Dueñas L; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A
    AIDS; 2013 Jul; 27(12):1941-7. PubMed ID: 23917425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
    Ioniţă-Radu F; Raşcanu A; Cheiab B
    Rom J Intern Med; 2011; 49(2):99-104. PubMed ID: 22303600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.
    Lötsch J; Hofmann WP; Schlecker C; Zeuzem S; Geisslinger G; Ultsch A; Doehring A
    Pharmacogenomics; 2011 Dec; 12(12):1729-40. PubMed ID: 22118055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.
    Berger CT; Kim AY
    Infect Dis Clin North Am; 2012 Dec; 26(4):863-77. PubMed ID: 23083820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.
    Holmes JA; Sievert W; Thompson AJ
    Biomark Med; 2011 Aug; 5(4):461-78. PubMed ID: 21861668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.
    Gouda HM; El-Saadany ZA; Foad NB; Salama RM
    DNA Cell Biol; 2014 Sep; 33(9):642-6. PubMed ID: 24999753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
    Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A
    J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.